Home > Boards > US Listed > Biotechs > RedHill Biopharma Ltd. (RDHL)

Indeed, I was thinking the same.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Spideyboy Member Profile
 
Followed By 12
Posts 912
Boards Moderated 0
Alias Born 04/07/08
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/15/2021 11:20:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/14/2021 2:29:29 PM
RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering PR Newswire (US) - 1/14/2021 2:13:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/14/2021 9:22:31 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/13/2021 5:10:30 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 1/12/2021 8:57:39 AM
RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million PR Newswire (US) - 1/12/2021 8:51:00 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 1/11/2021 4:52:52 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/11/2021 4:48:14 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/11/2021 4:45:32 PM
RedHill Biopharma Announces $10 Million Bought Deal Offering PR Newswire (US) - 1/11/2021 4:35:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/11/2021 7:00:29 AM
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D PR Newswire (Canada) - 1/11/2021 7:00:00 AM
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D PR Newswire (US) - 1/11/2021 7:00:00 AM
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D PR Newswire (US) - 1/11/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/6/2021 7:00:43 AM
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease PR Newswire (US) - 1/6/2021 7:00:00 AM
RedHill Releases ‘Positive’ Results From Early Covid-19 Trial With Opaganib; Shares Drop 5.6% TipRanks - 1/1/2021 3:05:29 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/31/2020 9:30:59 AM
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire (US) - 12/31/2020 9:30:00 AM
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire (US) - 12/31/2020 9:30:00 AM
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire (Canada) - 12/31/2020 9:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/22/2020 7:00:59 AM
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue PR Newswire (US) - 12/22/2020 7:00:00 AM
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue PR Newswire (Canada) - 12/22/2020 7:00:00 AM
Spideyboy   Friday, 07/24/20 10:54:22 AM
Re: vautee2910 post# 2101
Post # of 2752 
Indeed, I was thinking the same.

Odd. As I remember from the last earnings call, Dror specifically stated that while they weren't going to release the sales figures of Talicia at that moment as they we recently coming in, he said that 'Shareholders would not be disappointed' in a very upbeat manner.

Let's see what happens

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences